Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)

NCT04944121 is registered in ClinicalTrials.gov with Resolve Therapeutics as lead sponsor.

NCT NCT04944121
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04944121 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Placebo-controlled Study of RSLV-132 in Subjects With Post-acute COVID-19 (Long COVID)
Lead sponsor
Resolve Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
June 25, 2021
Completion date
November 30, 2023
Enrollment
112 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

post-acute corona virus 19 (covid-19) (long covid)